VivoSeq
Ophthalmology

Open-Angle Glaucoma

38

Pipeline Programs↗

7

Active Trials↗

17

Companies Involved↗

Open-Angle Glaucoma is a moderately active landscape with 38 programs across 17 companies. The most active players are EyeD Pharma, Takeda, Roche. 17 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

15/100

Mech. Concentration

23/100

Completion Rate

79/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

EyeD Pharma

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical6

Brimonidine Tartrate

AbbVie

Metformin

EMD Serono

MEMOPTIC

Centre Hospitalier Universitaire, Amiens

Usual Treatment of Glaucoma

Centre Hospitalier Universitaire, Amiens

Ginkgo Biloba

National Center for Complementary and Integrative Health (NCCIH)

Phase 16

Artificial Tears

University Hospital of Patras

Ranibizumab

Roche

Insulin

Merck & Co.

ANX007

Annexon, Inc.

SHP639 (n=60)

Takeda

Phase 23

Anecortave Acetate

Alcon Research

Mexidol

Pharmasoft

DE-117 Ophthalmic Solution QD

Santen Inc.

Phase 36

Citicoline

University of Texas Southwestern Medical Center

Brimonidine

Novartis

Dorzolamide-Timolol

Wills Eye

Reference - LUMIGAN

Amneal Pharmaceuticals, LLC

PRO-122

Laboratorios Sophia S.A de C.V.

Approved17

Memantine

AbbVie

Semaglutide

Novo Nordisk

Latanoprost

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Bimatoprost

AbbVie

Timolol

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Analysis

Modality Breakdown

95%

Small molecule

42 of 44 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody12%Peptide12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 100% of 46 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed15 · 52%
Active, not recruiting5 · 17%
Unknown status3 · 10%
Terminated2 · 7%
Withdrawn2 · 7%
Recruiting2 · 7%

Clinical Trials

Trial Activity

29 trials

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye
Recruiting·UUniversiti Sains Malaysia·Phase 4·NCT07396441·60 enrolled
A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
Recruiting·GGlostrup University Hospital, Copenhagen·Phase 4·NCT06792422·126 enrolled
Safety of Topical Insulin Drops for Open-angle Glaucoma
Active, not recruiting·—·Phase 1·NCT04118920·18 enrolled
A Study of PER-001 in Participants With Open-Angle Glaucoma
Active, not recruiting·PPerfuse Therapeutics, Inc.·Phase 1/2·NCT05822245·36 enrolled
GLAUCO-TECH Study: Safety & Efficacy of Preservative-free vs. Preserved Dorzolamide-Timolol-Brimonidine. Impact on the Ocular Surface, Glaucoma Progression, Tear Proteomics, and AI/Chatbot-led Patient Follow-up.
Active, not recruiting·TTecnoquimicas·Approved·NCT07690397·140 enrolled
An Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Biodegradation Period of PA5346 Ocular Implant, 115mcg When Administered to Patients With Open-Angle Glaucoma or Ocular Hypertension
Active, not recruiting·PPolyActiva Pty Ltd·Phase 1·NCT06964061·12 enrolled
A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Active, not recruiting·QQlaris Bio, Inc.·Preclinical·NCT07354516·60 enrolled
Anecortave Acetate in Patients With Open-angle Glaucoma
Completed·AAlcon Research·Phase 2·NCT00320203·86 enrolled
A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma
Completed·OOphthalmic Consultants Centres, Canada·Phase 4·NCT00887029·54 enrolled
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
Completed·AAnnexon, Inc.·Phase 1·NCT03488550·9 enrolled
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Completed·AbbVie logoAbbVie·N/A·NCT00716742·1,099 enrolled
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
Completed·AbbVie logoAbbVie·Phase 4·NCT01243567·81 enrolled
Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma
Completed·MMaisonneuve-Rosemont Hospital·Phase 2·NCT02376114·19 enrolled
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
Completed·PPharmasoft·Phase 2·NCT06903156·102 enrolled
Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
Completed·GGlaukos Corporation·Phase 4·NCT00913029·192 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)